Company Overview
By using the body’s immune system, Anixa Biosciences is taking multiple approaches to fighting cancer—developing both diagnostics and therapeutics to detect cancer early, when it is most curable, and to treat those afflicted once diagnosed.
Recent News
Anixa Biosciences Announces Positive Phase 1 Data for Investigational Breast Cancer Vaccine; Primary Endpoints Were Met and Immune Response Observed in 74% of Participants
Anixa Biosciences to Participate in Water Tower Research Fireside Chat on Monday, December 15, 2025
Anixa Biosciences Announces World Health Organization (WHO) Approval of International Non-Proprietary Name for its CAR-T Therapy, Marking a Key Milestone Toward Global Recognition and Future Commercialization
Stock Overview
Symbol
ANIX
Exchange
Nasdaq
Market Cap
117.84m
Last Price
$3.58
52-Week Range
$2.07 - $5.4566
12/12/2025 09:00 PM EST
Investor Relations
Mike Catelani
President, COO & CFO
T: 408-708-9808